期刊文献+

吉西他滨联合顺铂治疗26例复发性卵巢癌 被引量:3

Combination of Gemcitabine and Cisplatin in the Treatment for 26 Cases with Recurrent Ovarian Carcinoma
原文传递
导出
摘要 [目的]评价吉西他滨联合顺铂治疗复发性卵巢癌的疗效和毒副反应。[方法]2007年10月至2009年6月经手术和病理证实的复发性卵巢癌患者26例,采用吉西他滨1000mg/m2,静脉滴注30min,第1、8d;顺铂75mg/m2,分为第1、2、3d静脉滴注,每21d为1个疗程。观察近期疗效和毒副反应。[结果]随访3~17个月,总有效率38.46%(10/26),其中CR3例,PR7例,SD8例,PD8例。最常见的毒副反应是骨髓抑制和胃肠道毒性,主要为Ⅰ度、Ⅱ度。无化疗毒性相关性死亡。[结论]吉西他滨联合顺铂治疗复发性卵巢癌有一定的疗效,毒副反应可耐受。
作者 童玮如 赵霖
出处 《肿瘤学杂志》 CAS 2010年第4期310-311,共2页 Journal of Chinese Oncology
  • 相关文献

参考文献9

  • 1Rustin GJ, Quinn M, Thigpen T, et al. Re: New guidelines to evaluate the response to treatment in solid tumors(ovarian cancer)[J]. J Natl Cancer Inst, 2004, 96(6):487-488.
  • 2Vergote I, Rustin GJ, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)gynecologic cancer intergroup [J]. J Natl Cancer Inst, 2000, 92(18): 1534-1535.
  • 3Shapiro JD, Millward Mj, Rischin D, et al. Activity of gemeitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel[J].Gynecol Oncol, 1996, 63(1):89-93.
  • 4Moufarij MA, Phillips DR, Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines[J]. Mol Pharmacol, 2003, 63(4) : 862-869.
  • 5Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: A phase Ⅱ study of the Gynecologic Oncology Group[J]. Gynecol Oncol, 2006, 103(2):446-450.
  • 6Bozas G, Bamias A, Kout Soukou V, et al. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma [J]. Gynecol Oncol, 2007, 104(3): 580-585.
  • 7Tewari D, Monk B J, Hunter M, et al. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma[J]. Invest New Drugs, 2004, 22(4): 475-480.
  • 8Lehoczky O, Pulay T. Experience with gemcitabine-carboplatin chemotherapy in relapsed ovarian cancer [J]. Orv Hetil, 2006, 147(30): 1405-1408.
  • 9吴小华.NCCN2009年中国版卵巢癌、宫颈癌临床实践指南更新简介[J].中国妇产科临床杂志,2009,10(5):400-400. 被引量:6

同被引文献15

  • 1RUSTIN GJ,QUINN M,THIGPEN T,et al.New guide-lines to evaluate the response to treatment in solid tumors(ovarian cancer)[J].J Natl Cancer Inst,2004,96:487-488.
  • 2VERGOTE I,RUSTIN GJ,EISENHAUER EA,et al.Newguidelines to evaluate the response to treatment in solidtumors(ovarian cancer)gynecologic cancer intergroup[J].J Natl Cancer Inst,2000,92:1534-1535.
  • 3HERTEL LW,BODER GB,KROIN IS,et al.Evaluation ofthe antitumor activity of gemcitabine[J].Cancer Res,1990,50(14):4417-4422.
  • 4SHAPIRO JD,MILLWARD MJ,RISCHIN D,et al.Activityof gemcitabine in patients with advanced ovarian cancer:responses seen following platinum and paclitaxel[J].Gynecol Oncol,1996,63(1):89-93.
  • 5MOUFARU MA,PHILLIPS DR,CULUNANE C.Gemc-itabine potentiates cisplatin cytotoxicity and inhibits repair ofcisplatin-DNA damage in ovarian cancer cell lines[J].MolPharmacol,2003,63(4):862-869.
  • 6TEWARI D,MONK BJ,HUNTER M,et al.Gemcitabineand cisplatin chemotherapy is an active combination in thetreatment of platinum resistant ovarian and peritonealcarcinoma[J].Invest New Drugs,2004,22(4):475-480.
  • 7Sinpkins F,Belinson JL,Rose PG. Avoiding bevacizum abrelated gastro in testinal toxicity f or recrrent ovarian cancer by careful patient screening[J].Gynecologic Oncology,2007,(01):118-123.
  • 8Burger RA,SillMW,Monk BJ. Phase & trial of bevacizum ab in persistent or recu rren t epithelial ovari an cancer or primary peritoneal cancer:a Gynecologic Oncology Group St udy[J].J Clin Oncol,2007,(33):5165-5171.
  • 9Cannistra SA,Matulon is UA,Penson RT. PhaseII study of bevacizum ab in patients w ith platinum-resistant ovarian cancer or peritoneal serous cancer[J].Journal of Clinical Oncology,2007,(33):5180-5186.
  • 10张再军,杜宇.贝伐单抗联合化疗用于晚期结直肠癌临床观察[J].中国医药指南,2011,9(8):190-191. 被引量:7

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部